Everest Medicines Limited (HKG: 1952)

Market Cap	12.98B
Revenue (ttm)	449.73M
Net Income (ttm)	-1.13B
Shares Out	322.15M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,000
Average Volume	6,312,771
Open	40.65
Previous Close	40.65
Day's Range	39.75 - 40.70
52-Week Range	14.34 - 52.85
Beta	1.82
RSI	45.70
Earnings Date	Mar 28, 2025

About Everest Medicines

Everest Medicines Limited, a biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 432
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1952

Financial Performance

In 2023, Everest Medicines's revenue was 125.93 million, an increase of 884.46% compared to the previous year's 12.79 million. Losses were -844.46 million, 241.5% more than in 2022.

Financial numbers in CNY